Breaking News Instant updates and real-time market news.

TBPH

Theravance Biopharma

$22.18

-0.65 (-2.85%)

, GSK

GlaxoSmithKline

$39.85

-0.6 (-1.48%)

16:13
04/19/18
04/19
16:13
04/19/18
16:13

Theravance Biopharma reports publication of study of Treleggy Ellipta in COPD

Theravance Biopharma (TBPH) highlighted the publication in the New England Journal of Medicine of the landmark IMPACT study of Trelegy Ellipta in patients with chronic obstructive pulmonary disease. Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single Ellipta inhaler. Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innovivam formerly Theravance, Inc. Theravance Biopharma is entitled to receive an 85% economic interest in the royalties paid by GSK on worldwide net sales. Those royalties are upward-tiering from 6.5% to 10%, resulting in cash flows to Theravance Biopharma of approximately 5.5% to 8.5% of worldwide net sales of Trelegy Ellipta. Results from additional secondary and other endpoints published in the NEJM include: a statistically significant 34% reduction in COPD hospitalizations for Trelegy compared to Anoro and a reduction of 13% compared to Relvar/Breo which was not statistically significant ; a 42.1% reduction in the risk of on-treatment all-cause mortality was observed for Trelegy compared to Anoro. The safety profile of single inhaler triple therapy was consistent with the safety profile of the individual components. Trelegy Ellipta is approved in Europe as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA. The product is also approved for use in the US for the long-term, once-daily, maintenance treatment of COPD patients who are receiving Breo and require additional bronchodilation or who are receiving Breo and Incruse. Regulatory applications for Trelegy Ellipta have been submitted and are undergoing assessments in a number of other countries.

TBPH

Theravance Biopharma

$22.18

-0.65 (-2.85%)

GSK

GlaxoSmithKline

$39.85

-0.6 (-1.48%)

  • 20

    Apr

  • 23

    Apr

  • 25

    Apr

  • 08

    May

  • 18

    May

  • 21

    May

  • 13

    Nov

TBPH Theravance Biopharma
$22.18

-0.65 (-2.85%)

05/10/17
LEER
05/10/17
NO CHANGE
Target $47
LEER
Outperform
Theravance Biopharma price target raised to $47 from $34 at Leerink
Leerink analyst Geoffrey Porges raised his price target Theravance Biopharma to $47 from $34 after the company reported Q1 financial results and provided an update for investors about its development progress and upcoming milestones. The analyst reiterates an Outperform rating on the shares.
06/16/17
CANT
06/16/17
INITIATION
Target $55
CANT
Overweight
Theravance Biopharma initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Theravance Biopharma with an Overweight rating and $55 price target.
08/16/17
EVER
08/16/17
INITIATION
Target $45
EVER
Outperform
Theravance Biopharma initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Theravance Biopharma with an Outperform and a $45 price target.
03/29/18
PIPR
03/29/18
INITIATION
Target $45
PIPR
Overweight
Theravance Biopharma assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren assumed coverage of Theravance Biopharma with an Overweight rating and $45 price target. The company's respiratory products Trelegy and revefenacin "provide solid valuation support with the potential for significant upside" from its proprietary 1473/JAK and 9855/nOH development candidate, the analyst contends. He has confidence in the Trelegy launch and revefenacin approval and recommends investors buy the shares.
GSK GlaxoSmithKline
$39.85

-0.6 (-1.48%)

03/22/18
MSCO
03/22/18
UPGRADE
MSCO
Equal Weight
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier upgraded GlaxoSmithKline to Equal Weight and raised his price target for the shares to GBP 14 from GBP 13. The company's capital allocation strategy and operational repositioning show "clear signs of improvement," Meunier tells investors in a research note. Further, the analyst believes comments by the CEO suggest a large consumer deal is less likely than several months ago, which he believes reduces the risk of a dividend cut.
03/22/18
03/22/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Axle (AXL) and BorgWarner (BWA) were double-upgraded to Overweight from Underweight at Morgan Stanley. 2. GlaxoSmithKline (GSK) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Vincent Meunier saying the company's capital allocation strategy and operational repositioning show "clear signs of improvement." 3. General Mills (GIS) upgraded to Hold from Sell at Societe Generale with analyst Warren Ackerman citing valuation for the upgrade following yesterday's post-earnings selloff. 4. Pandora (P) upgraded to Strong Buy from Market Perform at Raymond James with analyst Justin Patterson saying AdsWizz will expand TAM by 2x to $28B, accelerate tech initiatives, materially expand reach, and could be worth approximately $4 per share. 5. Southwest (LUV) upgraded to Buy on valuation at Buckingham with analyst Daniel McKenzie saying shares are oversold and maintained a $70 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/18
EXAN
04/04/18
UPGRADE
EXAN
Outperform
GlaxoSmithKline upgraded to Outperform from Neutral at Exane BNP Paribas
Exane BNP Paribas analyst Kerry Holford upgraded GlaxoSmithKline to Outperform with an increased price target of GBP 16.30.
04/04/18
04/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Buy from Hold at HSBC. 2. GlaxoSmithKline (GSK) upgraded to Outperform from Neutral at Exane BNP Paribas. 3. BHP Billiton (BHP) upgraded to Sector Perform from Underperform at RBC Capital and to Buy from Neutral at Citi. 4. Boston Beer (SAM) upgraded to Market Perform from Underperform at Cowen with analyst Vivien Azer citing strong Nielsen data in the non-beer category. 5. EnLink Midstream Partners (ENLK) upgraded to Overweight from Neutral at JPMorgan with analyst Jeremy Tonet saying he reduced his distribution growth expectations given the elevated cost of equity, but views the current 11.5% yield as sustainable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PFE

Pfizer

$42.41

0.45 (1.07%)

12:56
02/17/19
02/17
12:56
02/17/19
12:56
Hot Stocks
Pfizer, EMD Serono announce publication of Phase 3 data for BAVENCIO plus INLYTA »

Merck KGaA, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 18

    May

MRK

Merck

$79.84

0.9 (1.14%)

, PFE

Pfizer

$42.41

0.45 (1.07%)

12:48
02/17/19
02/17
12:48
02/17/19
12:48
Hot Stocks
Merck presents results from Phase 3 KEYNOTE-426 study »

Merck (MRK) announced…

MRK

Merck

$79.84

0.9 (1.14%)

PFE

Pfizer

$42.41

0.45 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 11

    Apr

  • 18

    May

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

12:42
02/17/19
02/17
12:42
02/17/19
12:42
Hot Stocks
Aveo Pharmaceuticals presents TIVO-3 trial topline results »

Aveo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDM

Aradigm

$0.00

(0.00%)

12:34
02/17/19
02/17
12:34
02/17/19
12:34
Hot Stocks
Aradigm announces plans for reorganization under Chapter 11 »

Aradigm has filed for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

, XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

13:26
02/16/19
02/16
13:26
02/16/19
13:26
Periodicals
Amazon a risk for almost every stock/sector, Barron's says »

Amazon (AMZN) is eating…

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

KR

Kroger

$29.50

0.54 (1.86%)

FAST

Fastenal

$62.97

0.61 (0.98%)

GWW

Grainger

$316.63

4.9 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.